PD-L1/CD274 Polyclonal antibody 17952-1-AP proteintech

$149.00
In stock
SKU
17952-1-AP
Catalog No.SizePrice (USD)
17952-1-AP-20UL20 μL$149.00
17952-1-AP-150UL150 μL$449.00
Catalog Number17952-1-AP
SynonymsCD274, PD-L1, B7 H1, B7-H1, hPD-L1
HostRabbit
Reactivityhuman, mouse, rat
FormLiquid
FormulationPBS, Azide, Glycerol
ApplicationsWB, IHC, IF-P, IP, CoIP, ChIP, ELISA
ApplicationsWB, IHC, IF-P, IP, ELISA
Host / IsotypeRabbit / IgG
Tested Applications — Positive WB detected inhuman placenta tissue, A375 cells, IFN gamma treated A549 cells, HepG2 cells, K-562 cells, mouse heart tissue, mouse skeletal muscle tissue, rat kidney tissue
Tested Applications — Positive IP detected inmouse heart tissue
Tested Applications — Positive IHC detected inhuman tonsillitis tissue, human stomach cancer tissue, mouse heart tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Tested Applications — Positive IF-P detected inhuman tonsillitis tissue
Recommended Dilutions — Western Blot (WB)WB : 1:500-1:1000
Recommended Dilutions — Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Recommended Dilutions — Immunohistochemistry (IHC)IHC : 1:1000-1:4000
Recommended Dilutions — Immunofluorescence (IF)-PIF-P : 1:50-1:500
Positive WB detected inhuman placenta tissue, A375 cells, IFN gamma treated A549 cells, HepG2 cells, K-562 cells, mouse heart tissue, mouse skeletal muscle tissue, rat kidney tissue
Positive IP detected inmouse heart tissue
Positive IHC detected inhuman tonsillitis tissue, human stomach cancer tissue, mouse heart tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF-P detected inhuman tonsillitis tissue
Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:1000-1:4000
Immunofluorescence (IF)-PIF-P : 1:50-1:500
Tested Reactivityhuman, mouse, rat
Cited Reactivityhuman, mouse, rat
ClassPolyclonal
TypeAntibody
ImmunogenCatNo: Ag12432 Product name: Recombinant human PD-L1/CD274 protein Source: e coli. -derived, PGEX-4T Tag: GST Domain: 25-241 aa of BC074984 Sequence: KDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHL Predict reactive species
Full NameCD274 molecule
Calculated Molecular Weight290 aa, 33 kDa
Observed Molecular Weight45-56 kDa, 65-70 kDa
GenBank Accession NumberBC074984
Gene SymbolPD-L1
Gene ID (NCBI)29126
RRIDAB_10597552
ConjugateUnconjugated
Purification MethodAntigen affinity purification
UNIPROT IDQ9NZQ7
Storage BufferPBS with 0.02% sodium azide and 50% glycerol, pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20 o C storage. 20ul sizes contain 0.1% BSA.
IF protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IHC protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IP protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
WB protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
humanWB,IHC,IF Mol Ther Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy Authors - Kang Sun View Article
mouse,humanIHC,IF Acta Pharm Sin B Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors. Authors - Kuan Hu View Article
Citations264
DilutionsWB : 1:500-1:1000 IP : 0.5-4.0 ug for IP and 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate for WB IHC : 1:1000-1:4000 IF-P : 1:50-1:500
IsotypeIgG
ClonalityPolyclonal
Clone Number-
ConjugationUnconjugated

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. What is the molecular weight of PD-L1? Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa). What are the isoforms of PD-L1? According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. What is the subcellular localization and tissue specificity of PD-L1? It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. What is the function of PD-L1 in immune responses? PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). How can PD-L1's implication in cancer be used as a drug target? In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375). Protocols Product Specific Protocols IF protocol for PD-L1/CD274 antibody 17952-1-AP Download protocol IHC protocol for PD-L1/CD274 antibody 17952-1-AP Download protocol IP protocol for PD-L1/CD274 antibody 17952-1-AP Download protocol WB protocol for PD-L1/CD274 antibody 17952-1-AP Download protocol Standard Protocols Click here to view our Standard Protocols

Publications

  1. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
    Journal: Nat Biomed Eng | Authors: Han Yao | Species: human | Application: WB
  2. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1
    Journal: Nat Commun | Authors: Wenfeng Ren | Species: human | Application: IHC
  3. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
    Journal: Adv Sci (Weinh) | Authors: Shi-Wei Huang | Species: human | Application: WB
  4. Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors.
    Journal: Acta Pharm Sin B | Authors: Kuan Hu | Species: mouse,human | Application: IHC,IF
  5. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
    Journal: Mol Cell | Authors: Xin Jin | Species: human | Application: WB,IHC,IF
  6. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy
    Journal: Mol Ther | Authors: Kang Sun | Species: human | Application: WB,IHC,IF
  7. Single-cell multi-omic and spatial profiling of esophageal squamous cell carcinoma reveals the immunosuppressive role of GPR116+ pericytes in cancer metastasis
    Journal: Nat Genet | Authors: Xiaoya Pei | Species: mouse | Application: IF
  8. The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.
    Journal: Cell Mol Immunol | Authors: Rilin Deng | Species: human | Application: WB,IF
  9. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
    Journal: Cancer Res | Authors: Lydia Meder | Species: mouse | Application: IHC
  10. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.
    Journal: Nat Commun | Authors: Yimeng Ren | Species: mouse,human | Application: IHC,IF
  11. A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
    Journal: Nat Commun | Authors: Youmei Xiao | Species: mouse | Application: IF
  12. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1
    Journal: Nat Commun | Authors: Wenfeng Ren | Species: human | Application: IHC
  13. IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.
    Journal: Nat Commun | Authors: Shao-Wei Lu | Species: mouse | Application: IHC,IF
  14. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.
    Journal: Nat Commun | Authors: Yimeng Ren | Species: mouse,human | Application: IHC,IF
  15. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1
    Journal: Nat Commun | Authors: Wenfeng Ren | Species: human | Application: IHC
  16. Modulating Lysine Crotonylation in Cardiomyocytes Improves Myocardial Outcomes
    Journal: Circ Res | Authors: Wenqian Cai | Species: mouse | Application: IF
  17. The IFNγ-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension
    Journal: Circ Res | Authors: Lance N Benson | Species: mouse | Application: WB
  18. Remodeling of Effector and Regulatory T Cells by Capture and Utilization of miRNAs Using Nanocomposite Hydrogel for Tumor-Specific Photothermal Immunotherapy
    Journal: ACS Nano | Authors: Li Chen | Species: mouse | Application: WB
  19. Remodeling of Effector and Regulatory T Cells by Capture and Utilization of miRNAs Using Nanocomposite Hydrogel for Tumor-Specific Photothermal Immunotherapy
    Journal: ACS Nano | Authors: Li Chen | Species: mouse | Application: WB
  20. Triggered Cascade-Activation Nanoplatform to Alleviate Hypoxia for Effective Tumor Immunotherapy Guided by NIR-II Imaging
    Journal: ACS Nano | Authors: Yu Ji | Species: mouse | Application: IHC
  21. An Engineered Nanovesicles-Based Lysosome-Targeting Protein Degradation Platform (NV-TACs) for Cancer Immunotherapy.
    Journal: J Am Chem Soc | Authors: Youmei Xiao | Species: mouse | Application: IF
  22. PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy.
    Journal: Redox Biol | Authors: Sijin Liu | Species: human | Application: WB
  23. A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice
    Journal: Mol Cell | Authors: Xiaoding Ma | Species: mouse,human | Application: WB,IF
  24. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
    Journal: Mol Cell | Authors: Xin Jin | Species: human | Application: WB,IHC,IF
  25. Fusobacterium nucleatum-driven CX3CR1+ PD-L1+ phagocytes route to tumor tissues and reshape tumor microenvironment
    Journal: Gut Microbes | Authors: Fangfang Chen | Species: mouse,human | Application: IHC,IF
  26. Reprogramming tumor-associated macrophages and blocking PD-L1 via engineered outer membrane vesicles to enhance T cell infiltration and cytotoxic functions
    Journal: J Nanobiotechnology | Authors: Zhiqiang Chen | Species: mouse | Application: IHC
  27. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells
    Journal: J Nanobiotechnology | Authors: Hua‑Zhen Xu | Species: mouse,human | Application: WB,IHC
  28. CuOTeDsP nanotherapeutics enhance cuproptosis-mediated immunotherapy by modulating cholesterol metabolism in bladder cancer.
    Journal: J Nanobiotechnology | Authors: Hai Cai | Species: mouse | Application: WB
  29. Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.
    Journal: Theranostics | Authors: Yujia Zhao | Species: mouse | Application: IF
  30. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
    Journal: Theranostics | Authors: Jingyao Tu | Species: mouse | Application: WB
  31. Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors.
    Journal: Acta Pharm Sin B | Authors: Kuan Hu | Species: mouse,human | Application: IHC,IF
  32. Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment
    Journal: J Exp Clin Cancer Res | Authors: Yuyi Chen | Species: mouse | Application: IHC
  33. CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer
    Journal: J Exp Clin Cancer Res | Authors: Zixuan Li | Species: human | Application: WB
  34. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
    Journal: J Exp Clin Cancer Res | Authors: Crescenzo D'Alterio | Species: mouse | Application: IHC
  35. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Journal: J Exp Clin Cancer Res | Authors: Simona Camorani | Species: human | Application: WB,IHC
  36. BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer
    Journal: J Exp Clin Cancer Res | Authors: Weiwei Yuan | Species: mouse,human | Application: WB,IHC
  37. FAPα(+) Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence.
    Journal: Adv Sci (Weinh) | Authors: Huiyao Gu | Species: mouse | Application: IHC
  38. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
    Journal: Adv Sci (Weinh) | Authors: Shi-Wei Huang | Species: human | Application: WB
  39. UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD-L1 Transcription.
    Journal: Adv Sci (Weinh) | Authors: Huichan Xue
  40. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
    Journal: Adv Sci (Weinh) | Authors: Hong Zhang | Species: human | Application: WB
  41. METTL7A Downregulation Drives SLC1A5-Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8(+) T Cell Immunity in Gastric Cancer.
    Journal: Adv Sci (Weinh) | Authors: Mingjun Sun
  42. Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors.
    Journal: Cell Rep Med | Authors: Dun Niu | Species: mouse | Application: IF
  43. Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors.
    Journal: Cell Rep Med | Authors: Dun Niu | Species: mouse | Application: IF
  44. Ara-C suppresses H3 K27-altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity
    Journal: Sci Adv | Authors: Bo Pang | Species: human | Application: WB,IF
  45. PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity.
    Journal: Sci Adv | Authors: Ye Liu | Species: mouse | Application: WB
  46. Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs.
    Journal: Biomaterials | Authors: In Seon Jeon | Species: mouse | Application: WB
  47. Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes.
    Journal: Biomaterials | Authors: Li Jia | Application: WB
  48. Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy
    Journal: Biomaterials | Authors: Haoyu Guo | Species: human | Application: IHC
  49. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Journal: Biomaterials | Authors: Pan Zhang | Species: mouse | Application: WB,IHC
  50. Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes.
    Journal: Biomaterials | Authors: Li Jia | Application: WB
  51. DDX10 Exacerbates Exosomal PD-L1-Dependent T Cell Exhaustion via Phase Separation of Rab27b in Oral Squamous Cell Carcinoma
    Journal: Research (Wash D C) | Authors: Bowen Li | Species: mouse,human | Application: WB
  52. A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy
    Journal: J Control Release | Authors: Yue Sun | Species: mouse | Application: WB,IF
  53. KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
    Journal: Cell Death Dis | Authors: Jinghan Li | Species: mouse,human | Application: WB,IHC,IF
  54. STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells
    Journal: Cell Death Dis | Authors: Je-Jung Lee | Species: mouse,human | Application: WB,IF
  55. CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer.
    Journal: Cell Death Dis | Authors: Jhen-Yu Chen | Species: human | Application: WB
  56. Immune Checkpoint Reprogramming via Sequential Nucleic Acid Delivery Strategy Optimizes Systemic Immune Responses for Gastrointestinal Cancer Immunotherapy
    Journal: Cancer Lett | Authors: Zhuoyuan Li | Species: mouse | Application: IHC,IF
  57. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment
    Journal: J Immunother Cancer | Authors: Yuan Meng | Species: human | Application: WB
  58. THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.
    Journal: J Immunother Cancer | Authors: Chushu Li | Species: mouse,human | Application: WB,IHC,IF
  59. Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.
    Journal: J Immunother Cancer | Authors: Yuwei Deng | Species: human | Application: IHC
  60. Aberrant Expression of SLC7A11 Impairs the Antimicrobial Activities of Macrophages in Staphylococcus Aureus Osteomyelitis in Mice
    Journal: Int J Biol Sci | Authors: Bingsheng Yang | Species: mouse | Application: WB
  61. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment
    Journal: J Immunother Cancer | Authors: Yuan Meng | Species: human | Application: WB
  62. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Journal: J Immunother Cancer | Authors: Xisha Chen | Species: human | Application: WB,IHC
  63. The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer.
    Journal: Int J Biol Sci | Authors: Naijin Xu | Species: human | Application: WB
  64. Disruption of FGL2 induces TFEB-dependent lysosomal degradation of PD-L1 and enhances the efficacy of anti-PD1 therapy in hepatocellular carcinoma.
    Journal: Cell Commun Signal | Authors: Meiwen Han | Species: human | Application: IF
  65. PD-1/PD-L1 blockade is a potent adjuvant in treatment of Staphylococcus aureus osteomyelitis in mice
    Journal: Mol Ther | Authors: Kaiqun Li | Species: mouse,human | Application: WB,IHC,IF
  66. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy
    Journal: Mol Ther | Authors: Kang Sun | Species: human | Application: WB,IHC,IF
  67. Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling.
    Journal: Phytomedicine | Authors: Yu Zhang | Species: mouse | Application: WB
  68. Indole-3-carbinol inhibits PD-L1-mediated immune evasion in hepatocellular carcinoma via suppressing NF-κB p105 Ubiquitination
    Journal: Phytomedicine | Authors: Yongkang Wu | Species: mouse,human | Application: WB
  69. Qingshen granules inhibits dendritic cell glycolipid metabolism to alleviate renal fibrosis via PI3K-AKT-mTOR pathway
    Journal: Phytomedicine | Authors: Wen-Jing Zhou | Species: mouse | Application: WB
  70. Light-enhanced Hypoxia-responsive Gene Editing for Hypoxia-resistant Photodynamic And Immunotherapy
    Journal: Adv Healthc Mater | Authors: Suchen Qu | Species: mouse | Application: WB
  71. In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy.
    Journal: Mater Today Bio | Authors: Jiehan Li | Species: mouse | Application: WB
  72. TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1.
    Journal: Clin Cancer Res | Authors: Cai Zhang | Species: human | Application: WB
  73. TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1.
    Journal: Clin Cancer Res | Authors: Cai Zhang | Species: human | Application: WB
  74. PD-L1/PD-1 checkpoint pathway regulates astrocyte morphogenesis and myelination during brain development
    Journal: Mol Psychiatry | Authors: Yanyan Wang | Species: mouse
  75. MS1-96 induces HIP1R-dependent PD-L1 degradation and promotes antitumor immunity in colorectal cancer.
    Journal: Acta Pharmacol Sin | Authors: Jin-Jin Peng | Species: mouse | Application: IHC
  76. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
    Journal: Diabetologia | Authors: Emi Kawada-Horitani | Species: mouse,human | Application: IHC
  77. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
    Journal: Acta Biomater | Authors: Qianwen Yu | Species: mouse | Application: IHC
  78. RBM47 promotes cell proliferation and immune evasion by upregulating PDIA6: a novel mechanism of pancreatic cancer progression
    Journal: J Transl Med | Authors: Yihui Ma | Species: human | Application: WB
  79. Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma.
    Journal: J Colloid Interface Sci | Authors: Xinwei Kuang | Species: mouse,human | Application: WB,IF
  80. Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.
    Journal: Oncogene | Authors: Chushu Li | Species: mouse | Application: IHC
  81. Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
    Journal: Oncogene | Authors: Peixin Dong | Species: human | Application: WB
  82. TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity
    Journal: Oncogene | Authors: Jing-Lan Hao | Species: mouse | Application: IHC
  83. Epoxyazadiradione exhibit activities in head and neck squamous cell carcinoma by targeting multiple pathways.
    Journal: Apoptosis | Authors: Vipin Rai | Species: human | Application: WB
  84. Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs.
    Journal: Apoptosis | Authors: Nikee Awasthee | Species: human | Application: WB
  85. Anti-tumor effect of PD-L1-targeting antagonistic aptamer-ASO delivery system with dual inhibitory function in immunotherapy
    Journal: Cell Chem Biol | Authors: Fatao Luo | Species: human | Application: WB
  86. Circular RNA CDYL facilitates hepatocellular carcinoma stemness and PD-L1+ exosomes-mediated immunotherapy resistance via stabilizing hornerin protein by blocking synoviolin 1-mediated ubiquitination
    Journal: Int J Biol Macromol | Authors: Jingbo Fu | Application: WB
  87. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
    Journal: Int J Nanomedicine | Authors: Yezi Chen | Species: mouse | Application: IF
  88. Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer
    Journal: Mol Med | Authors: Ju-Young Han | Species: human | Application: WB,IHC
  89. Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
    Journal: Cell Mol Gastroenterol Hepatol | Authors: Kyo Sasaki | Species: human | Application: IHC
  90. Metabolic Syndrome Develops Cardia Cancer via Nuclear Factor-E2-related Factor 2-Programmed Death-Ligand 1 Signaling.
    Journal: Cell Mol Gastroenterol Hepatol | Authors: Keisuke Kusano | Species: mouse | Application: WB,IHC
  91. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Journal: Eur J Cancer | Authors: Ching-Yao Yang | Species: human | Application: IHC
  92. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Journal: Eur J Cancer | Authors: Ching-Yao Yang | Species: human | Application: IHC
  93. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
    Journal: Eur J Cancer | Authors: Yih-Leong Chang | Species: human | Application: IHC
  94. Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.
    Journal: Cancer Immunol Res | Authors: Chiao-Jung Kao | Species: mouse | Application: IHC
  95. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Journal: Cancer Immunol Res | Authors: Zhen Tao | Species: human | Application: WB,IHC
  96. A Novel 3D in Vitro Tumor Model Based on Silk Fibroin/Chitosan Scaffolds To Mimic the Tumor Microenvironment.
    Journal: ACS Appl Mater Interfaces | Authors: Jizhao Li | Species: human | Application: WB
  97. Isoliquiritigenin Suppresses Breast Tumor Development by Enhancing Host Antitumor Immunity
    Journal: Am J Chin Med | Authors: Chun-Lu Yuan | Species: mouse,human | Application: WB,IHC
  98. Bifidobacterium infantis regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease
    Journal: World J Gastroenterol | Authors: Lin-Yan Zhou | Species: mouse | Application: WB
  99. Seno-antigen-pulsed dendritic cell vaccine induce anti-aging immunity to improve adipose tissue senescence and metabolic abnormalities
    Journal: Biomed Pharmacother | Authors: Yin Cao | Species: mouse | Application: WB
  100. Effects of three-dimensional collagen scaffolds on the expression profiles and biological functions of glioma cells.
    Journal: Int J Oncol | Authors: Wei Jia | Species: human | Application: WB
  101. Ursodeoxycholic Acid Platinum(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2/STAT3 Signaling
    Journal: J Med Chem | Authors: Yan Chen | Species: mouse | Application: WB
  102. Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties
    Journal: J Med Chem | Authors: Bin Sun | Species: mouse | Application: WB,IHC
  103. Rational Design of PROTAC Degraders and Their Spatiotemporal Controlled Delivery for Enhanced Tumor Penetration and PD-L1 Protein Degradation.
    Journal: J Med Chem | Authors: Qianqian Qi | Species: mouse | Application: WB
  104. Formin protein DAAM1 positively regulates PD-L1 expression via mediating the JAK1/STAT1 axis in pancreatic cancer
    Journal: Cancer Cell Int | Authors: Rui Xu | Species: human | Application: WB,IF
  105. Anti-melanoma effects of concomitant inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL mice.
    Journal: J Invest Dermatol | Authors: Gagan Chhabra | Species: human | Application: IHC
  106. Bifidobacterium infantis Promotes Foxp3 Expression in Colon Cells via PD-L1-Mediated Inhibition of the PI3K-Akt-mTOR Signaling Pathway.
    Journal: Front Immunol | Authors: Linyan Zhou | Species: human | Application: WB,IHC
  107. Mycobacterium abscessus-Bronchial Epithelial Cells Cross-Talk Through Type I Interferon Signaling.
    Journal: Front Immunol | Authors: Chongxu Zhang | Species: mouse | Application: IHC
  108. Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.
    Journal: Front Immunol | Authors: Kaiyuan Wang | Species: human | Application: IHC
  109. Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive black phosphorus
    Journal: Drug Deliv Transl Res | Authors: Hua-Zhen Xu | Species: mouse | Application: IHC
  110. Huangqi Jianzhong decoction inhibits CRC invasion through the modulation of BCLAF1-mediated glycolysis.
    Journal: J Ethnopharmacol | Authors: Xinlu Liu | Species: human | Application: WB
  111. Jianpi-huayu Decotion regulates TREM1/DAP12 pathway to improve the immunosuppressive tumor microenvironment and enhance the anti-hepatocellular carcinoma effect of PD-1 inhibitors.
    Journal: J Ethnopharmacol | Authors: Ruiwei Yao | Species: mouse | Application: IHC
  112. PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.
    Journal: CNS Neurosci Ther | Authors: Hao Zhang | Species: human | Application: IHC
  113. Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT
    Journal: Biochem Pharmacol | Authors: Xing Chang | Species: mouse,human | Application: WB,IHC
  114. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
    Journal: Life Sci | Authors: Zhuo Liu | Species: mouse | Application: WB,IF
  115. The crosstalk between lung adenocarcinoma cells and M2 macrophages promotes cancer cell development via the SFRS1/miR-708-5p/PD-L1 axis
    Journal: Life Sci | Authors: Li Xu | Species: human | Application: IF
  116. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
    Journal: Oncoimmunology | Authors: Masahiro Kikuchi | Species: human | Application: IHC
  117. Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.
    Journal: Oncoimmunology | Authors: Sushil Kumar | Species: mouse | Application: IHC
  118. Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid
    Journal: Oncoimmunology | Authors: Siyu Li | Species: mouse | Application: IHC
  119. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
    Journal: Gastric Cancer | Authors: Chan Jin Yoon | Species: human | Application: WB
  120. Cinobufagin Inhibits Invasion and Migration of Non-Small Cell Lung Cancer via Regulating Glucose Metabolism Reprogramming in Tumor-Associated Macrophages.
    Journal: Drug Des Devel Ther | Authors: Ying Sun | Species: human | Application: IF
  121. The Immune Checkpoint Protein PD-L1 Regulates Ciliogenesis and Hedgehog Signaling
    Journal: Cells | Authors: Ewud Agborbesong | Species: mouse,human | Application: WB,IF
  122. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Journal: Int J Pharm | Authors: Wen-Jun Wan | Species: mouse | Application: WB
  123. Immune Checkpoint-Blocking Nanocages Cross the Blood-Brain Barrier and Impede Brain Tumor Growth
    Journal: ACS Biomater Sci Eng | Authors: Minseong Kim | Species: human
  124. Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21.
    Journal: Gene Ther | Authors: Haojie Wang | Species: human | Application: WB
  125. HKDC1 promotes ovarian cancer progression through boosting lipid metabolism and immune escape by stabilizing G6PC/G6PC2
    Journal: Commun Biol | Authors: Ying Wang | Species: human | Application: WB,IF
  126. TGF-β inhibition enhances anti-tumor immunity and sensitizes PD-1 blockade therapy of bone marrow-derived myofibroblasts-induced "immunotherapy resistance" tumor model.
    Journal: Cancer Immunol Immunother | Authors: Xin Cheng
  127. TGF-β inhibition enhances anti-tumor immunity and sensitizes PD-1 blockade therapy of bone marrow-derived myofibroblasts-induced "immunotherapy resistance" tumor model.
    Journal: Cancer Immunol Immunother | Authors: Xin Cheng
  128. Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model
    Journal: Radiother Oncol | Authors: Jun Yeong Song | Species: human | Application: IHC
  129. Circ_0074158 and QKI6: A regulatory axis for PD-L1 ubiquitination and immune evasion in NSCLC.
    Journal: Cancer Immunol Immunother | Authors: Haihua Zhang | Species: human | Application: WB,IP,FC
  130. Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy
    Journal: Cancer Immunol Immunother | Authors: Jhen-Yu Chen | Species: human | Application: WB
  131. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer
    Journal: Eur J Pharmacol | Authors: Ying Yu | Species: mouse,human | Application: WB,IHC
  132. Targeting the ZDHHC9-mediated STAT1 palmitoylation-phosphorylation conversion inhibits gastric cancer progression.
    Journal: J Gastroenterol | Authors: Xiao Bai | Species: human | Application: WB,IHC
  133. Targeting the ZDHHC9-mediated STAT1 palmitoylation-phosphorylation conversion inhibits gastric cancer progression.
    Journal: J Gastroenterol | Authors: Xiao Bai | Species: human | Application: WB,IHC
  134. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer
    Journal: Eur J Pharmacol | Authors: Ying Yu | Species: mouse,human | Application: WB,IHC
  135. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
    Journal: Int Immunopharmacol | Authors: Xiaomin Cai | Species: human | Application: IHC
  136. Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma
    Journal: Int Immunopharmacol | Authors: Ke Shao | Species: human | Application: WB,IHC
  137. IL-17A/IL-17RA interaction blockade sensitizes synovial macrophages to efferocytosis and PD-L1 signaling via rewiring STAT-3/ADAM17/MERTK axis in rheumatoid arthritis animal model.
    Journal: Int Immunopharmacol | Authors: Snigdha Samarpita | Species: rat | Application: WB,IF
  138. Colorectal cancer cell-derived exosomal miRNA-372-5p induces immune escape from colorectal cancer via PTEN/AKT/NF-κB/PD-L1 pathway
    Journal: Int Immunopharmacol | Authors: Yulun Wu | Species: human | Application: WB,IHC
  139. PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model.
    Journal: Int Immunopharmacol | Authors: Yanxin Chen | Species: mouse | Application: IHC
  140. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
    Journal: Int Immunopharmacol | Authors: Xiaomin Cai | Species: human | Application: IHC
  141. S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway
    Journal: Cell Oncol (Dordr) | Authors: Xianwei Zhou | Species: human | Application: WB
  142. PD-1/PD-L1 axis is involved in the interaction between microglial polarization and glioma
    Journal: Int Immunopharmacol | Authors: Xi-Peng Wang | Species: rat | Application: WB,IF
  143. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
    Journal: Int Immunopharmacol | Authors: Lijun Wu | Species: human | Application: WB,IF
  144. Analysis of Oral and Gut Microbiome Composition and Its Impact in Patients with Oral Squamous Cell Carcinoma
    Journal: Int J Mol Sci | Authors: Kensaku Matsui | Species: human | Application: IHC
  145. S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway
    Journal: Cell Oncol (Dordr) | Authors: Xianwei Zhou | Species: human | Application: WB
  146. Pterostilbene as a pyroptosis inducer and tumor microenvironment regulator inhibits glioblastoma and enhances the efficacy of immunotherapy.
    Journal: Int Immunopharmacol | Authors: Zhuo Chen | Species: human,mouse | Application: WB
  147. Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation
    Journal: Front Pharmacol | Authors: Taisuke Kaiho | Species: mouse | Application: IHC
  148. PLA-THF-PEG nanoparticles Co-encapsulating AV3 and KH3 for synergistic pancreatic cancer therapy via stromal remodeling and metabolic inhibition.
    Journal: Front Pharmacol | Authors: Xiaorong Liu | Species: human | Application: WB
  149. A Quinoxaline Derivative as a New Therapeutic Agent for Sepsis through Suppression of TLR4 Signaling Pathways
    Journal: Inflammation | Authors: Hamza Hanieh | Species: mouse | Application: WB
  150. Interferon Regulatory Factor 2 (IRF2) Suppression Enhances Murine Cardiac Allograft Survival Through Immune Evasion.
    Journal: Immunology | Authors: Li Tian | Species: mouse | Application: IHC
  151. PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
    Journal: Oncotarget | Authors: Shengwei Liu | Species: human | Application: IHC
  152. miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression.
    Journal: Oncotarget | Authors: Susheng Miao | Species: human | Application: IHC
  153. Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Patients With Resected Lung Adenocarcinoma.
    Journal: Ann Thorac Surg | Authors: Jung-Jyh Hung | Species: human | Application: IHC
  154. Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation
    Journal: J Nutr Biochem | Authors: Han Zhang | Species: mouse,human | Application: WB
  155. Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression
    Journal: J Nutr Biochem | Authors: Qi Zhang | Species: mouse,human | Application: WB,IHC
  156. Triplet radio-chemo-immunotherapy reprograms the PD-L1-CDK6 axis to remodel the tumor microenvironment and overcome immune resistance in head and neck cancer.
    Journal: Eur J Pharm Sci | Authors: Chin-Sheng Huang
  157. The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
    Journal: Oncotarget | Authors: Haitao Yang | Species: Human
  158. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
    Journal: Oncotarget | Authors: Yih-Leong Chang | Species: human | Application: IHC
  159. Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model.
    Journal: Sci Rep | Authors: Chongxu Zhang | Species: human | Application: IF
  160. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors
    Journal: Mol Pharm | Authors: Lulu Zhang | Species: mouse | Application: WB,IHC,IF
  161. Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice.
    Journal: Sci Rep | Authors: Kazunori Tokuda | Species: mouse | Application: IHC,IF
  162. Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer
    Journal: Transl Oncol | Authors: Xiaoming Yang | Species: mouse | Application: IHC
  163. Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer
    Journal: Transl Oncol | Authors: Xiaoming Yang | Species: mouse | Application: IHC
  164. Angiotensin-converting enzyme 2 identifies immuno-hot tumors suggesting angiotensin-(1-7) as a sensitizer for chemotherapy and immunotherapy in breast cancer
    Journal: Biol Proced Online | Authors: Jie Mei | Species: human | Application: WB,IHC
  165. KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8(+) T cells in colorectal cancer.
    Journal: Sci Rep | Authors: Yajie Du | Species: human | Application: WB
  166. Bispecific antibody simultaneously targeting AGR2 and PD1 mediates cytotoxic T-cell-induced antitumor response in AGR2-dependent manner and inhibits AGR2-induced PDL1 upregulation
    Journal: Sci Rep | Authors: Debmalya Roy | Species: human | Application: WB
  167. DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL-18
    Journal: Cancer Sci | Authors: Xiaofan Duan | Species: mouse | Application: IHC
  168. Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice.
    Journal: Sci Rep | Authors: Kazunori Tokuda | Species: mouse | Application: IHC,IF
  169. Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice.
    Journal: Sci Rep | Authors: Kazunori Tokuda | Species: mouse | Application: IHC,IF
  170. miR-4759 suppresses breast cancer through immune checkpoint blockade.
    Journal: Comput Struct Biotechnol J | Authors: You-Zhe Lin | Species: mouse,human | Application: WB,IHC
  171. Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-rasG12D Transgenic Mice.
    Journal: Cancers (Basel) | Authors: Shan-Ming Chen | Species: mouse | Application: IHC
  172. Induction of Immunological Antitumor Effects by the Combination of Adenovirus-Mediated Gene Transfer of B7-1 and Anti-Programmed Cell Death-1 Antibody in a Murine Squamous Cell Carcinoma Model
    Journal: Cancers (Basel) | Authors: Makiko Hara | Species: human | Application: IF
  173. Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models.
    Journal: Cancers (Basel) | Authors: Jin Wang | Species: mouse | Application: IHC
  174. Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation
    Journal: Cancers (Basel) | Authors: Steve Seung-Young Lee | Species: mouse | Application: IF
  175. Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer
    Journal: Neoplasia | Authors: Yaqi Gao | Species: human | Application: IHC,IF
  176. Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation
    Journal: Cancers (Basel) | Authors: Steve Seung-Young Lee | Species: mouse | Application: IF
  177. Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma
    Journal: Oncol Rep | Authors: Hui Zeng | Species: human | Application: IHC
  178. Exosomal PIK3CB promotes PD-L1 expression and malignant transformation in esophageal squamous cell carcinoma
    Journal: Med Oncol | Authors: Wei Xu | Species: human | Application: WB
  179. Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma.
    Journal: Oncol Rep | Authors: Zhuo Liu | Species: human | Application: WB
  180. Differentiation of cancer cells upregulates HLA‑G and PD‑L1.
    Journal: Oncol Rep | Authors: Matti Ullah | Species: human | Application: IF
  181. MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
    Journal: Oncol Rep | Authors: Ming Cheng | Species: human | Application: WB
  182. KLF4 mediates the contradictory effects of phenylethyl isothiocyanate in gastric cancer intervention
    Journal: Med Oncol | Authors: Qi Zhang | Species: human,mouse | Application: WB,IHC
  183. GALNT6 dual regulates innate immunity STING signaling and PD-L1 expression to promote immune evasion in pancreatic ductal adenocarcinoma
    Journal: Cell Signal | Authors: Suli Chong | Species: human | Application: WB,IP,IF
  184. High Infiltration of CD203c+ Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer
    Journal: J Inflamm Res | Authors: Jing Li | Species: human | Application: IHC
  185. Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes
    Journal: iScience | Authors: Jinfeng Wang | Species: human | Application: WB,IHC
  186. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis
    Journal: iScience | Authors: Rilin Deng | Species: mouse,human | Application: WB,CoIP
  187. PD-1/PD-L1 inhibits M1 polarization of microglia and macrophages through STAT1/NF-κB and Akt/mTOR signaling pathways.
    Journal: Brain Res Bull | Authors: Qian Zhang | Species: mouse | Application: IF
  188. Treatment Response to Oncolytic Virus in Patient-Derived Breast Cancer and Hypopharyngeal Cancer Organoids: Evaluation via a Microfluidics Organ-on-a-Chip System
    Journal: Bioengineering (Basel) | Authors: Yu Sun | Species: human | Application: WB,IF
  189. Prostate fibroblasts and prostate cancer associated fibroblasts exhibit different metabolic, matrix degradation and PD-L1 expression responses to hypoxia
    Journal: Front Mol Biosci | Authors: Jesus Pacheco-Torres | Species: mouse | Application: IHC
  190. In vivo transfection of cytokine genes into tumor cells using a synthetic vehicle promotes antitumor immune responses in a visceral tumor model
    Journal: FASEB J | Authors: Shunichi Watanabe | Species: mouse | Application: IF
  191. Metformin Enhances PD-L1 Inhibitor Efficacy in Ovarian Cancer by Modulating the Immune Microenvironment and RBMS3 Expression
    Journal: FASEB J | Authors: Qingsong Zhang
  192. Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
    Journal: Antiviral Res | Authors: Tianying Wang | Species: mouse,human | Application: WB
  193. Astragaloside IV Enhances Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer by Activating the cGAS-STING Pathway.
    Journal: Drug Dev Res | Authors: Chuanchao Wei | Species: human,mouse | Application: WB
  194. Metformin as an anti-cancer agent against bladder cancer acts via PD-L1 downregulation in an orthotopic mouse model
    Journal: BMC Cancer | Authors: Chang-Ching Yeh
  195. Blue light irradiation inhibits the M2 polarization of the cancer-associated macrophages in colon cancer
    Journal: BMC Cancer | Authors: Toshiaki Yoshimoto | Species: mouse | Application: IHC
  196. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
    Journal: BMC Cancer | Authors: Xi Chen | Species: human | Application: IF
  197. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
    Journal: J Pathol Clin Res | Authors: Sara Sf Al-Badran | Species: human | Application: IHC
  198. PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT
    Journal: BMC Cancer | Authors: Wenjuan Li | Species: human | Application: WB,IHC
  199. Bifidobacterium infantis Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease.
    Journal: Gut Liver | Authors: Linyan Zhou | Species: mouse | Application: WB
  200. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Journal: Oral Oncol | Authors: Tseng-Cheng Chen | Species: human | Application: IHC
  201. Turning to immunosuppressive tumors: Deciphering the immunosenescence-related microenvironment and prognostic characteristics in pancreatic cancer, in which GLUT1 contributes to gemcitabine resistance
    Journal: Heliyon | Authors: Si-Yuan Lu | Species: human | Application: IHC
  202. CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.
    Journal: J Cell Physiol | Authors: Shutao Zheng | Species: human | Application: WB,IHC
  203. IFN-β Pretreatment Alleviates Allogeneic Renal Tubular Epithelial Cell-Induced NK Cell Responses via the IRF7/HLA-E/NKG2A Axis
    Journal: J Immunol | Authors: Xing Zhang | Species: mouse | Application: IHC
  204. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Journal: Clin Lung Cancer | Authors: Kazuki Takada | Species: human
  205. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Journal: Clin Lung Cancer | Authors: Kazuki Takada | Species: human
  206. Membranous translocation of murine double minute 2 promotes the increased renal tubular immunogenicity in ischemia-reperfusion-induced acute kidney injury
    Journal: Am J Physiol Renal Physiol | Authors: Jieyu Zeng | Species: rat,human | Application: IHC,IF
  207. Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.
    Journal: J Biochem Mol Toxicol | Authors: Xirong Lu | Species: human | Application: WB
  208. FBXO22 is a potential therapeutic target for recurrent chondrosarcoma
    Journal: J Bone Oncol | Authors: Baoquan Xin | Species: human | Application: WB,IHC
  209. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Journal: Diagn Pathol | Authors: Euno Choi | Species: human | Application: IHC
  210. Linarin Suppresses the Progression of Colorectal Cancer by Inhibiting the HIF-1α/PD-L1 Axis.
    Journal: Mol Carcinog | Authors: Hao Wang | Species: human | Application: WB,IF
  211. Linarin Suppresses the Progression of Colorectal Cancer by Inhibiting the HIF-1α/PD-L1 Axis.
    Journal: Mol Carcinog | Authors: Hao Wang | Species: human | Application: WB,IF
  212. A pan-cancer portrait of PDK1: From oncogenic driver to context-dependent immunological regulator.
    Journal: Cancer Treat Res Commun | Authors: Shuangshuang Duan | Species: human | Application: IHC
  213. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Journal: Diagn Pathol | Authors: Euno Choi | Species: human | Application: IHC
  214. Inhibition of PD-L1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process
    Journal: Exp Cell Res | Authors: Yuqi Shi | Species: mouse | Application: WB
  215. Helicobacter urease suppresses cytotoxic CD8 + T cell responses through activating Myh9-dependent induction of PD-L1.
    Journal: Int Immunol | Authors: Jian Wu | Species: human | Application: IF
  216. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
    Journal: Cancer Prev Res (Phila) | Authors: Jin Wang | Species: mouse | Application: IHC,IF
  217. Helicobacter urease suppresses cytotoxic CD8 + T cell responses through activating Myh9-dependent induction of PD-L1.
    Journal: Int Immunol | Authors: Jian Wu | Species: human | Application: IF
  218. Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer
    Journal: Front Oncol | Authors: Bridget E Crossman | Application: WB
  219. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
    Journal: Cancer Prev Res (Phila) | Authors: Jin Wang | Species: mouse | Application: IHC,IF
  220. PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.
    Journal: Front Oncol | Authors: Fan Yang | Species: human | Application: IHC
  221. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Journal: Front Oncol | Authors: Huarong Cai | Species: human | Application: IHC
  222. Activity of the growth hormone-releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis-like granuloma
    Journal: Clin Transl Immunology | Authors: Chongxu Zhang | Species: mouse | Application: IHC
  223. MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment.
    Journal: Mol Cell Probes | Authors: Hongmei Yong | Species: human | Application: WB
  224. Small extracellular vesicles derived from PD-L1-modified mesenchymal stem cell promote Tregs differentiation and prolong allograft survival.
    Journal: Cell Tissue Res | Authors: Qifeng Ou | Species: rat | Application: WB
  225. Cetirizine platinum(IV) complexes with antihistamine properties inhibit tumor metastasis by suppressing angiogenesis and boosting immunity
    Journal: J Inorg Biochem | Authors: Yan Chen | Species: mouse | Application: WB
  226. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
    Journal: J Vasc Interv Radiol | Authors: Haruyuki Takaki | Species: rat | Application: IHC
  227. Ablation of ASF1B mitigates the proliferation of A549 cells and enhances anti-PD-L1 therapy by regulating ferroptosis.
    Journal: Tissue Cell | Authors: Jiamin Shi | Species: human | Application: WB,IHC
  228. Platycodin D reduces PD-L1 levels by inhibiting LXR-β activity and combines with nintedanib to enhance the tumor-killing effect of T cells
    Journal: FEBS Lett | Authors: Jin Lei | Species: human | Application: WB
  229. Antibiotics treatment promotes squamocolumnar junction tumor progression via tumor immune evasion in K19-Wnt1/C2mE mice fed high-fat diet and acidic bile salts.
    Journal: Am J Physiol Gastrointest Liver Physiol | Authors: Koya Ogasawara | Species: mouse | Application: WB,IHC
  230. Vaccine Against Gastrin, Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases.
    Journal: Am J Physiol Gastrointest Liver Physiol | Authors: Nicholas Osborne | Species: mouse | Application: IHC
  231. A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.
    Journal: PLoS One | Authors: Marisa R Buchakjian | Species: mouse | Application: IHC
  232. Study on the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109.
    Journal: Discov Oncol | Authors: Shang Peng | Species: human | Application: IHC
  233. Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma.
    Journal: Genes Nutr | Authors: Mingjing Peng | Species: human | Application: WB
  234. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
    Journal: Clin Transl Oncol | Authors: S Hua | Species: human | Application: WB
  235. Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.
    Journal: Immunol Res | Authors: Long Jiang | Species: human | Application: IHC
  236. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
    Journal: Clin Transl Oncol | Authors: S Hua | Species: human | Application: WB
  237. PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
    Journal: Cancer Manag Res | Authors: Jinfeng Wang | Species: human | Application: IHC
  238. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1
    Journal: Thorac Cancer | Authors: Wei Tian | Species: human | Application: WB
  239. Expression of PD-L1 Is Increased by Methionine Restriction Using Recombinant Methioninase in Human Colorectal Cancer Cells
    Journal: Cancer Genomics Proteomics | Authors: Kohei Mizuta | Species: human | Application: WB
  240. BGC823 Cell Line with the Stable Expression of iRFP720 Retains Its Primary Properties with Promising Fluorescence Imaging Ability.
    Journal: DNA Cell Biol | Authors: Han Hu | Species: human | Application: IHC
  241. MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.
    Journal: Biochem Biophys Res Commun | Authors: Xianglu Ji | Species: mouse,human | Application: WB
  242. An effective tumor-inhibiting siRNA delivery platform.
    Journal: Biochem Biophys Res Commun | Authors: Qixin Leng | Species: human | Application: IHC,IF
  243. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
    Journal: Biochem Biophys Res Commun | Authors: Long Jia | Species: mouse | Application: WB
  244. Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.
    Journal: Onco Targets Ther | Authors: Jun Chen | Species: human | Application: IHC
  245. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
    Journal: Int J Biol Markers | Authors: Shu-Wei Chen | Species: human | Application: IHC
  246. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
    Journal: J Thorac Dis | Authors: Hai-Xia Qu | Species: Human
  247. MCT4/Lactate Promotes PD-L1 Glycosylation in Triple-Negative Breast Cancer Cells
    Journal: J Oncol | Authors: Xianxian Duan | Species: human | Application: WB
  248. Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells.
    Journal: J Oncol | Authors: Qiu-Ting Li | Species: human | Application: WB
  249. Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells.
    Journal: Pancreas | Authors: Tetsuya Ikemoto | Species: human | Application: IHC
  250. PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.
    Journal: Oncol Lett | Authors: Dan Lv | Species: human | Application: IHC
  251. PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis
    Journal: Transl Cancer Res | Authors: Woojoo Lee
  252. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.
    Journal: Oncol Lett | Authors: Lijuan Han | Species: human | Application: IHC
  253. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.
    Journal: Medicine (Baltimore) | Authors: Yaxiong Zhang | Species: human | Application: IHC
  254. Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Exerts Anti-Breast Cancer Effect via miR-200c-PDE7B/PD-L1-AKT/MAPK Axis.
    Journal: Evid Based Complement Alternat Med | Authors: Yue Yang | Species: mouse | Application: WB
  255. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
    Journal: Cancer Biomark | Authors: Ching-Yao Yang | Species: human | Application: IHC
  256. Methionine Restriction Alone Induces T-cell-mediated Immunotherapy of Osteosarcoma in a Syngeneic Mouse Model.
    Journal: In Vivo | Authors: KOHEI MIZUTA | Species: human,mouse | Application: WB
  257. Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p.
    Journal: Transpl Immunol | Authors: Qiangxing Chen | Species: rat | Application: WB
  258. Insulin-Like Growth Factor 1 Receptor Expression for Predicting PD‑1/PD‑L1 Inhibitor Response in Hypopharyngeal Squamous Cell Carcinoma.
    Journal: World J Otorhinolaryngol Head Neck Surg | Authors: Wen-Jing Li | Species: human | Application: IHC
  259. The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
    Journal: Oncotarget | Authors: Ziying Lin
  260. [Small interfering RNA-mediated programmed cell death-ligand 1 silencing in human glioma cells enhances human CD8+ T lymphocyte cytotoxicity in vitro].
    Journal: Nan Fang Yi Ke Da Xue Xue Bao | Authors: Zhen Wang | Species: human | Application: WB
  261. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
    Journal: Nanotheranostics | Authors: Christina K Lee | Species: mouse | Application: IHC
  262. Resilience and vulnerabilities of tumor cells under purine shortage stress
    Journal: bioRxiv | Authors: Jianpeng Yu | Species: human | Application: IHC
  263. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Journal: Oncotarget | Authors: Kyoung-Jin Kim | Species: human | Application: WB,IHC
  264. Loss of CFIm activates YAP/TAZ and connects mRNA cleavage and polyadenylation inhibition to BRCAness.
    Journal: bioRxiv | Authors: Madeleine Goldthorpe | Species: human | Application: WB
  265. Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy.
    Journal: J Control Release | Authors: Liqing Chen | Species: mouse | Application: WB,IHC

Reviews

Write Your Own Review
You're reviewing:PD-L1/CD274 Polyclonal antibody 17952-1-AP proteintech
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.